Research programme: BET inhibitors - Zenith Epigenetics Corp

Drug Profile

Research programme: BET inhibitors - Zenith Epigenetics Corp

Alternative Names: NexVas Autoimmune (AI) programme - Resverlogix; NexVas vascular inflammation; NexVas VI (vascular inflammation) therapy - Resverlogix; RVX-297

Latest Information Update: 24 Sep 2014

Price : $50

At a glance

  • Originator Resverlogix Corporation; Zenith Epigenetics Corp
  • Developer Zenith Epigenetics Corp
  • Class Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Cancer

Most Recent Events

  • 24 Sep 2014 Early research in Cancer in Canada (PO)
  • 03 Jun 2013 Resverlogix transfers ownership of this research programme to Zenith Epigenetics Corp
  • 27 Jun 2011 Interim pharmacodynamics data from a preclinical trial in Multiple sclerosis released by Resverlogix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top